December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.